DBV Technologies S.A.

DBVT ·Healthcare, Drug Manufacturers - General
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $5.6M $4.2M $15.7M $4.8M $5.7M $11.3M $14.7M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $116.7M $89.3M $60.2M $75.5M $70.3M $101.6M $115.1M
SG&A Expense $32.8M $28.7M $29.5M $24.3M $30.5M $35.1M $49.1M
Operating Income $-147.1M $-116.6M $-76.4M $-96.6M $-98.6M $-158.8M $-171.0M
Operating Margin -2,609.2% -2,808.7% -486.0% -1,994.9% -1,727.6% -1,408.7% -1,162.8%
Interest Expense
Pretax Income $-146.5M $-113.9M $-72.7M $-96.2M $-98.2M $-159.6M $-171.4M
Income Tax Expense $491.0K $55.0K $7.0K $70.0K $-381.0K $-10.0K $610.0K
Net Income $-146.9M $-113.9M $72.7M $96.3M $-97.8M $-159.6M $-172.0M
Net Margin -2,607.3% -2,744.4% 462.3% 1,987.5% -1,713.5% -1,415.0% -1,169.5%
EPS (Basic) $-1.05 $-1.17 $-0.76 $-1.24 $-1.78 $-2.95 $-4.65
EPS (Diluted) $-1.05 $-1.17 $-0.76 $-1.24 $-1.78 $-2.95 $-4.65
Shares Outstanding (Basic) 296.0M 139.6M 97.0M 95.1M 77.4M 54.9M 54.9M
Shares Outstanding (Diluted) 296.0M 139.6M 97.0M 95.1M 77.4M 54.9M 54.9M
Dividends Per Share